Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPIVITE vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Major depressive disorder,Generalized anxiety disorder,Panic disorder,Obsessive-compulsive disorder,Social anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder,Bulimia nervosa
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Hepatic via CYP2D6, CYP2C9, CYP3A4, and CYP2C19; major active metabolite: norfluoxetine.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5%
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
98% bound to albumin and alpha-1-acid glycoprotein
~10-20% bound to plasma proteins (primarily albumin).
Vd 0.25 L/kg (0.18-0.33 L/kg); indicates predominantly extracellular distribution
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 75% (range 60-85%); food decreases bioavailability by 20%
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
GFR >= 60 m L/min: no adjustment. GFR 30-59 m L/min: 1.2 mg/kg IV every 12 hours. GFR 15-29 m L/min: 0.8 mg/kg IV every 12 hours. GFR < 15 m L/min: 0.5 mg/kg IV every 12 hours.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh A: no adjustment. Child-Pugh B: 1.2 mg/kg IV every 12 hours. Child-Pugh C: 0.9 mg/kg IV every 12 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
2 mg/kg IV every 12 hours for children 1-12 years; maximum single dose 100 mg. For infants 1-12 months: 2.5 mg/kg every 12 hours.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Start at lowest adult dose; consider 1.2 mg/kg IV every 12 hours if Cr Cl >= 60 m L/min. Monitor renal function closely; reduce dose per renal adjustment if Cr Cl < 60 m L/min.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Serotonin syndrome; bleeding risk; activation of mania/hypomania; hyponatremia; QT prolongation; weight loss in children; sexual dysfunction; withdrawal reactions; drug interactions with MAOIs, other serotonergics.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Concurrent use with MAOIs or within 14 days of MAOI therapy; known hypersensitivity to fluoxetine; use with pimozide or thioridazine due to QT prolongation risk.
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid high-protein meals with enzyme as they may reduce effectiveness. Do not take with acidic foods (e.g., citrus, vinegar) which may degrade the enzyme. Alcohol may increase GI side effects.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
FDA Pregnancy Category X. First trimester: High risk of neural tube defects, cardiac anomalies, and cleft palate due to folate antagonism. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. Avoid in pregnancy.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Contraindicated in breastfeeding. M/P ratio not established; potential for infant toxicity due to accumulation in breast milk.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No safe dose in pregnancy. If inadvertent exposure, discontinue immediately and provide supportive care. Pharmacokinetic changes in pregnancy increase clearance by 30-40%, but contraindication overrides any dose adjustment.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
SERPIVITE (serrapeptase) is a proteolytic enzyme used for its anti-inflammatory and mucolytic effects. It is not a standard pharmaceutical; verify regulatory status. Monitor for bleeding risk when used with anticoagulants. Onset of action may be delayed; not for acute conditions. Use with caution in peptic ulcer disease.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take on an empty stomach at least 30 minutes before or 2 hours after meals.,Do not crush or chew enteric-coated tablets; swallow whole.,Report signs of bleeding (easy bruising, nosebleeds, blood in stool).,Avoid use if allergic to enzymes or if you have a bleeding disorder.,Consult healthcare provider before use if pregnant, breastfeeding, or on anticoagulants.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPIVITE vs ALDOMET, answered by our medical review team.
SERPIVITE is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPIVITE and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPIVITE is: 1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPIVITE and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPIVITE is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of neural tube defects, cardiac anomalies, and cleft palate due to folate antagonism. Second and third trimesters: Risk of feta. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.